[go: up one dir, main page]

WO2013177253A3 - Fatty acid synthase inhibitors - Google Patents

Fatty acid synthase inhibitors Download PDF

Info

Publication number
WO2013177253A3
WO2013177253A3 PCT/US2013/042173 US2013042173W WO2013177253A3 WO 2013177253 A3 WO2013177253 A3 WO 2013177253A3 US 2013042173 W US2013042173 W US 2013042173W WO 2013177253 A3 WO2013177253 A3 WO 2013177253A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
acid synthase
synthase inhibitors
inhibitors
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/042173
Other languages
French (fr)
Other versions
WO2013177253A2 (en
Inventor
Nicholas David ADAMS
Terence John Kiesow
Kenneth Wiggall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of WO2013177253A2 publication Critical patent/WO2013177253A2/en
Anticipated expiration legal-status Critical
Publication of WO2013177253A3 publication Critical patent/WO2013177253A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed are compounds having Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, m, and n are defined herein and methods of using the same.
PCT/US2013/042173 2012-05-22 2013-05-22 Fatty acid synthase inhibitors Ceased WO2013177253A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650224P 2012-05-22 2012-05-22
US61/650,224 2012-05-22

Publications (2)

Publication Number Publication Date
WO2013177253A2 WO2013177253A2 (en) 2013-11-28
WO2013177253A3 true WO2013177253A3 (en) 2015-06-18

Family

ID=49624505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/042173 Ceased WO2013177253A2 (en) 2012-05-22 2013-05-22 Fatty acid synthase inhibitors

Country Status (1)

Country Link
WO (1) WO2013177253A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149512A1 (en) * 2005-12-09 2007-06-28 Solvay Pharmaceuticals Gmbh N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
US20090281097A1 (en) * 2006-04-14 2009-11-12 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US20100160337A1 (en) * 2008-12-18 2010-06-24 Matthews Jay M Sulfamides as trpm8 modulators
WO2012064642A1 (en) * 2010-11-08 2012-05-18 Glaxosmithkline Llc Fatty acid synthase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149512A1 (en) * 2005-12-09 2007-06-28 Solvay Pharmaceuticals Gmbh N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
US20090281097A1 (en) * 2006-04-14 2009-11-12 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US20100160337A1 (en) * 2008-12-18 2010-06-24 Matthews Jay M Sulfamides as trpm8 modulators
WO2012064642A1 (en) * 2010-11-08 2012-05-18 Glaxosmithkline Llc Fatty acid synthase inhibitors

Also Published As

Publication number Publication date
WO2013177253A2 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
WO2012122011A3 (en) Amino-quinolines as kinase inhibitors
WO2011088027A8 (en) Compounds and methods
WO2014011911A3 (en) Irak inhibitors and uses thereof
WO2014011906A3 (en) Irak inhibitors and uses thereof
WO2014052563A3 (en) Novel compounds that are erk inhibitors
WO2011143772A9 (en) Inhibitors of hiv replication
WO2012158843A3 (en) Kinase inhibitors
HK1210696A1 (en) Irak inhibitors and uses thereof
WO2014100764A3 (en) Methods of inhibiting prmt5
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
EP2566477A4 (en) Amino-quinolines as kinase inhibitors
WO2013003298A3 (en) Inhibitors of pde10
WO2014124230A3 (en) Erk inhibitors and uses thereof
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
PH12014502169A1 (en) N-cyclylamides as nematicides
SG11201503646TA (en) Esterification of 2,5-furan-dicarboxylic acid
IN2014DN09346A (en)
CA2873723A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
EP3087184A4 (en) Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
WO2012101011A3 (en) New aryl-benzocycloalkyl amide derivatives
EA201590552A1 (en) AMINOHINOLINES AS KINASE INHIBITORS
EP2908636A4 (en) Compositions comprising peroxy acid
WO2017015433A3 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
WO2015077657A3 (en) Stat3 inhibitors and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13793844

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13793844

Country of ref document: EP

Kind code of ref document: A2